Contact
searchSearch
HMP Global

Medical Therapies News

Research Highlights
Combination Biologic and Small-Molecule Therapy Shows Promise in Refractory IBD, Meta-Analysis Finds
01/14/2026
Jessica Garlewicz
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis...
01/14/2026
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network

Latest News

Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Expert Insights
IBD Drive Time: Raymond Cross, MD, on Ostomy Complications
01/13/2026
Raymond Cross, MD; Sara Horst, MD
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive...
01/13/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Conference Coverage
IBD Drive Time: The Best of ACG With Dr Sara Horst
12/01/2025
Raymond Cross, MD; Sara Horst, MD
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive...
12/01/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Freddy Caldera, MD, on Vaccines for Patients With IBD
11/03/2025
Raymond Cross, MD; Freddy Caldera, DO
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to...
11/03/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Megan Riehl, PsyD, on Mental Health and IBD
10/22/2025
Raymond Cross, MD; Megan Riehl, PsyD
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Clinical psychologist Megan...
10/22/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Florian Rieder, MD, on Stricturing and Penetrating Crohn's Disease
10/06/2025
Raymond Cross, MD; Florian Rieder
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, welcomes...
10/06/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Jason Schairer, MD, on Extraintestinal Manifestations in IBD
09/25/2025
Jason Schairer, MD; Raymond Cross, MD
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and...
09/25/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Ryan Ungaro, MD, on Perturbances in Metabolic Pathways in IBD
09/02/2025
Raymond Cross, MD; Ryan Ungaro
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with...
09/02/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Anita Afzali, MD, on the ACG Guidelines for Crohn's Disease
08/18/2025
Raymond Cross, MD; Anita Afzali
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr...
08/18/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: David Rubin, MD, on the ACG Guidelines for Ulcerative Colitis
08/04/2025
David T. Rubin, MD; Raymond Cross, MD
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD,...
08/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Corey Siegel, MD, on Defining Quality Care for IBD
07/15/2025
Raymond Cross, MD; Corey A. Siegel, MD, MS
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr...
07/15/2025
Advances in Inflammatory Bowel Disease Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use